Is Zepbound better than Wegovy for weight loss?

In SURMOUNT-5, a 2025 head-to-head trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy). But averages hide individual variation, and Wegovy has cardiovascular-outcome data; the best choice depends on your health, tolerability, and cost. This is general information, not medical advice.

Are Zepbound and Wegovy the same drug?

No. Zepbound is tirzepatide (a dual GIP + GLP-1 agonist); Wegovy is semaglutide (a GLP-1 agonist). Both are once-weekly injections approved for chronic weight management, but they're different molecules from different makers.

Which is cheaper, Zepbound or Wegovy?

Both are high-cost brand-name injectables and pricing depends heavily on insurance coverage, manufacturer savings programs, and pharmacy. We don't quote live prices — check current pricing and your plan's coverage directly, and ask about manufacturer savings cards.

Zepbound vs Wegovy

By the pharmaranks editorial teamReviewed against FDA prescribing information (DailyMed) + pivotal trials (PubMed) sourcesUpdated Jul 3, 2026How we research

The two weight-management brands head-to-head: Zepbound (tirzepatide, dual GIP + GLP-1) vs Wegovy (semaglutide, GLP-1). In a 2025 trial, tirzepatide produced greater average weight loss.

At a glance

	Zepbound	Wegovy
Active drug	tirzepatide	semaglutide
Drug class	Dual GIP + GLP-1 receptor agonist	GLP-1 receptor agonist
FDA-approved for	Chronic weight management	Chronic weight management
How it's taken	Once-weekly injection	Once-weekly injection
Maker	Eli Lilly	Novo Nordisk

Zepboundrating & safety →·Wegovyrating & safety →

The short version

Zepbound and Wegovy are the two injectables FDA-approved specifically for chronic weight management. Zepbound is tirzepatide (Eli Lilly), a dual GIP + GLP-1 agonist; Wegovy is semaglutide (Novo Nordisk), a GLP-1 agonist. This is the closest thing to an apples-to-apples GLP-1 weight-loss comparison.

The key difference

Zepbound's dual mechanism is the main difference, and it showed up in outcomes: in SURMOUNT-5 (2025), a direct head-to-head, tirzepatide produced greater average weight loss than semaglutide. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity — Wegovy is not.

What the trials showed on weight

In their pivotal trials, Zepbound (tirzepatide 15 mg) averaged about 20–21% body-weight reduction (SURMOUNT-1) and Wegovy (semaglutide 2.4 mg) about 15% (STEP 1); the SURMOUNT-5 head-to-head favored tirzepatide. These are averages, not promises — side effects, cost, and coverage differ and results vary.

Bottom line

For average weight loss, the evidence favors Zepbound, including a direct head-to-head. But Wegovy has a longer track record and cardiovascular-outcome data, and tolerability and cost vary — the choice is individualized with a clinician. Not medical advice.

Frequently asked

Is Zepbound better than Wegovy for weight loss?: In SURMOUNT-5, a 2025 head-to-head trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy). But averages hide individual variation, and Wegovy has cardiovascular-outcome data; the best choice depends on your health, tolerability, and cost. This is general information, not medical advice.
Are Zepbound and Wegovy the same drug?: No. Zepbound is tirzepatide (a dual GIP + GLP-1 agonist); Wegovy is semaglutide (a GLP-1 agonist). Both are once-weekly injections approved for chronic weight management, but they're different molecules from different makers.
Which is cheaper, Zepbound or Wegovy?: Both are high-cost brand-name injectables and pricing depends heavily on insurance coverage, manufacturer savings programs, and pharmacy. We don't quote live prices — check current pricing and your plan's coverage directly, and ask about manufacturer savings cards.

Compare more GLP-1 options

Wegovy vs Ozempic Mounjaro vs Ozempic Zepbound vs Mounjaro Rybelsus vs Ozempic Mounjaro vs Wegovy All GLP-1 drugs compared →

Sources

General information, not medical advice, and not a substitute for your clinician. Efficacy figures are pivotal-trial averages — individual results, side effects, and cost vary. Only a licensed healthcare professional can choose, start, switch, or dose these medicines.